One contributing event to invasive progression could be TP53 mutation, as studies have consistently shown that TP53 mutations are less frequent in pure DCIS (15% on average, 0–32%) (63, 69, 70, 74–80) than IBC (27–37%) (81, 82). Here, TP53 is linked to ductal breast carcinoma in situ.